# Ubiquitination‐Driven Reprogramming of Proteostasis in Metastasis

## TL;DR

This paper reveals how the DCAF12–TRiC/CCT axis helps cancer cells survive and spread by improving protein folding under stress, offering new therapeutic strategies to target metastasis.

## Contribution

The paper introduces a non-degradative ubiquitination mechanism by DCAF12 that activates TRiC/CCT chaperonins to promote metastasis.

## Key findings

- DCAF12 ubiquitinates TRiC/CCT subunits to enhance their folding capacity and stability.
- The DCAF12–TRiC/CCT axis supports metastasis by enabling efficient proteome reprogramming.
- Targeting this axis could disrupt proteostatic resilience in advanced cancers.

## Abstract

Metastasis, the leading cause of cancer‐related mortality, poses a fundamental proteostatic challenge, requiring rapid and precise proteome remodeling in response to stress. While ubiquitination is linked to protein degradation, our recent work uncovered a non‐canonical, metastasis‐promoting mechanism centered on DCAF12, a substrate receptor of the Cullin 4–RING ubiquitin ligase complex. DCAF12 mediates non‐degradative ubiquitination of TRiC/CCT chaperonin subunits, allosterically activating the chaperonin to enhance its assembly, stability, and folding capacity. This ubiquitination‐dependent activation circuit enables metastatic cells to efficiently fold and stabilize diverse pro‐metastatic proteins, thereby facilitating dynamic proteome reprogramming. Herein, we present the DCAF12–TRiC/CCT axis as a central regulatory component of this adaptive response, explore its evolutionary basis, and propose DCAF12 as a prototype for a broader class of “DCAFome” regulators of chaperone function. This mechanistic understanding establishes a direct rationale for therapeutically targeting this axis to disrupt adaptive proteostasis. Moreover, we outline a therapeutic paradigm termed “proteostatic stress creation.” This framework encompasses a spectrum of strategies, from precision protein–protein interaction inhibitors to state‐selective degraders of DCAF12 or its ubiquitinated chaperonin subunits. These approaches can potentially disrupt the DCAF12–TRiC/CCT axis, thereby undermining the proteostatic resilience that sustains advanced cancers.

The DCAF12–TRiC/CCT axis is a key regulator of metastasis in cancer. By reprogramming proteostasis to ensure efficient protein folding, it drives progression through a dual mechanism: enhancing cancer cell motility and invasiveness while concurrently activating pro‐growth and survival pathways. This synergy between enhanced cellular movement and sustained pro‐tumor signaling facilitates robust and efficient metastatic spread.